Literature DB >> 20217604

Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes.

Miriam Rothdiener1, Julia Beuttler, Sylvia K E Messerschmidt, Roland E Kontermann.   

Abstract

Immunoliposomes generated by coupling of antibodies to the liposomal surface allow for an active tissue targeting, e.g., through binding to tumor cell-specific receptors. Instead of whole antibodies, single-chain Fv fragments (scFv), which represent the smallest part of an antibody containing the entire antigen-binding site, find increasing usage as targeting moiety. Here we provide protocols for the preparation of type II scFv immunoliposomes by the conventional coupling method as well as the post-insertion method. Furthermore protocols to analyze binding of these immunoliposomes to antigen-expressing cells as well as internalization through receptor-mediated endocytosis are included.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20217604     DOI: 10.1007/978-1-60761-609-2_20

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

Review 1.  Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations.

Authors:  Valentina Colapicchioni; Francesco Millozzi; Ornella Parolini; Daniela Palacios
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-29

2.  Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response.

Authors:  Mesha Saeed; Sara Zalba; Ann L B Seynhaeve; Reno Debets; Timo L M Ten Hagen
Journal:  Int J Nanomedicine       Date:  2019-03-26

3.  Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.

Authors:  Sara Zalba; María J Garrido; María Merino; Teresa Lozano; Noelia Casares; Hugo Lana; Iñaki F Troconiz; Timo L M Ten Hagen; Grazyna Kochan; Pedro Berraondo
Journal:  J Nanobiotechnology       Date:  2021-04-13       Impact factor: 10.435

4.  Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses.

Authors:  Joseph A Katakowski; Gayatri Mukherjee; Samantha E Wilner; Keith E Maier; Michael Travis Harrison; Teresa P DiLorenzo; Matthew Levy; Deborah Palliser
Journal:  Mol Ther       Date:  2015-09-28       Impact factor: 11.454

5.  Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody.

Authors:  Mesha Saeed; Mandy van Brakel; Sara Zalba; Erik Schooten; Joost A P Rens; Gerben A Koning; Reno Debets; Timo L M Ten Hagen
Journal:  Int J Nanomedicine       Date:  2016-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.